Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2018

View Archived Issues

Administration of erlotinib via soaked intraocular lenses prevents posterior capsule opacification

Actuate begins phase I/II trial of GSK-3beta inhibitor 9-ING-41 in advanced cancers

CDK7 inhibitor THZ-1 induces breast cancer-specific cell death by suppressing LIN9 expression

Targeting NKILA in CTLs as a promising new breast cancer immunotherapy strategy

Irisin and bone: good but complicated

Premature birth complication prevented by targeting microglia

FAAH inhibitor PF-04457845 ameliorates stress- and fear-related behavior in humans

HP-3070 is efficacious and safe for the treatment of schizophrenia in adults

Selatogrel significantly inhibits platelet aggregation in phase II studies

Pyramid Biosciences licenses TRK modulator from AstraZeneca

TK-90 shows promise for prevention of mucositis in clinical study

Corbus initiates phase III DETERMINE study based on phase II data in dermatomyositis

Positive phase II data presented in third proof-of-concept study of VX-150

First patient enrolled in pivotal phase III AGENT study of arfolitixorin

Topline data presented from phase Ia study of LX-9211

Spiral Therapeutics initiates phase I trial of new hearing loss drug, LPT-99

Eli Lilly patents OGA inhibitors

Myelin needs just the right amount of neighborliness

Enanta Pharmaceuticals divulges MAP3K5 inhibitors

DuoHexaBody-CD37 induces potent CDC in ex vivo B-cell lymphoma and leukemia patient samples

Abide Therapeutics identifies MGL inhibitors

CD45-AM ADC as promising new approach for safer conditioning prior to bone marrow transplant

Oxford University Innovation discovers beta-lactamase inhibitors as antibacterials

Taisho Pharmaceutical describes bacterial LpxC inhibitors

Phase III study of satralizumab in neuromyelitis optica spectrum disorder meets primary endpoint

Repigmentation therapy with Scenesse and NB-UVB effective in vitiligo

DMC recommends stopping phase III study of lumateperone for futility

Lilly signs collaboration and license agreement for Aduro's cGAS-STING pathway inhibitor program

PeptiDream and Nihon Medi-Physics enter peptide-radioisotope conjugate alliance

European Commission approves Dengvaxia for prevention of dengue

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...